Our results showed no significant correlation between PFS and the radiomic signature in EGFR-mutant NSCLC patients, indicating the specific stratification ability of the radiomic signature in predicting ALK-TKI resistance. The gene discussed is ALK; the disease is non-small cell lung carcinoma.